Want to see CLOV full AI Analyst Report?
CLOV Stock Chart & Stats
$4.13
-$0.23(-5.05%)
At close: 4:00 PM EDT
$4.13
-$0.23(-5.05%)
Day’s Range― - ―
52-Week Range$1.58 - $5.59
Previous CloseN/A
Volume2.96M
Average Volume (3M)4.08M
Market Cap
$2.26B
Enterprise Value$2.86K
Total Cash (Recent Filing)$201.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 09, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend Yield1.23%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding435,441,350
10 Day Avg. Volume3,235,501
30 Day Avg. Volume4,076,225
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.94
Price to Sales (P/S)0.63
P/FCF Ratio-17.62
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside27.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.04
Revenue Forecast (FY)$2.95B
Bulls Say, Bears Say
Bulls Say
Membership And Revenue GrowthRapid membership expansion and revenue growth strengthen operating scale, improve fixed-cost absorption, and expand Clover’s presence in Medicare Advantage. Sustained enrollment growth can support recurring premium revenue if medical-cost discipline and retention remain intact.
Debt-Free Balance Sheet And Cash GenerationA debt-free balance sheet and positive operating cash flow provide financial flexibility to fund technology, quality programs, and market growth internally. This reduces refinancing risk and gives Clover greater capacity to absorb medical-cost volatility or regulatory uncertainty.
Higher Medicare Advantage Star RatingsThe 4.5-star ratings can improve quality-linked payments, benefit flexibility, and competitive positioning in Medicare Advantage. If sustained, the upgrade should support plan economics and product attractiveness, although the final benefit depends on the ongoing CMS appeal.
Bears Say
Profitability Not Yet ConsistentDespite recent quarterly profits, Clover has not established durable full-year profitability. The insurance model remains exposed to medical-cost trends, pricing, and risk adjustment, so adverse utilization or pricing changes could quickly pressure earnings and equity.
Early-Stage Member Cohort Margin PressureA large share of members remains early in Clover’s lifecycle, when margins are expected to be weaker. Future economics depend on cohort maturation and effective care management, creating execution risk if clinical improvements or retention do not develop as expected.
CMS Appeal And Medical-Cost UncertaintyThe CMS appeal could reduce or delay the expected benefit from higher Star ratings, affecting payments and plan flexibility. Elevated outpatient utilization adds a separate structural risk because medical-cost inflation can erode margins before pricing or care interventions adjust.
Clover Health Investments News
CLOV FAQ
What was Clover Health Investments’s price range in the past 12 months?
Clover Health Investments lowest stock price was $1.58 and its highest was $5.59 in the past 12 months.
What is Clover Health Investments’s market cap?
Clover Health Investments’s market cap is $2.26B.
When is Clover Health Investments’s upcoming earnings report date?
Clover Health Investments’s upcoming earnings report date is Nov 09, 2026 which is in 64 days.
How were Clover Health Investments’s earnings last quarter?
Clover Health Investments released its earnings results on Aug 05, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.039 by $0.011.
Is Clover Health Investments overvalued?
According to Wall Street analysts Clover Health Investments’s price is currently Undervalued.
Does Clover Health Investments pay dividends?
Clover Health Investments pays a Notavailable dividend of $0.1 which represents an annual dividend yield of 1.23%. See more information on Clover Health Investments dividends here
What is Clover Health Investments’s EPS estimate?
Clover Health Investments’s EPS estimate is >-0.01.
How many shares outstanding does Clover Health Investments have?
Clover Health Investments has 435,441,350 shares outstanding.
What happened to Clover Health Investments’s price movement after its last earnings report?
Clover Health Investments reported an EPS of $0.05 in its last earnings report, beating expectations of $0.039. Following the earnings report the stock price went up 12.56%.
Which hedge fund is a major shareholder of Clover Health Investments?
Currently, no hedge funds are holding shares in CLOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Health Investments Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.25 (27.12% Upside)
$5.25 (27.12% Upside)
Blogger Sentiment
Neutral
CLOV Sentiment 57%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 9.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Clover Health Investments
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.
CLOV Company Deck
CLOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line and membership growth (48% MA growth, +56% revenue YoY in Q2), improving profitability (Q2 adjusted EBITDA $41M, GAAP net income $28M), expanded operating leverage, improved cash balance, and a favorable 4.5-star recalculation — all supported by visible cohort maturation dynamics (~$70 PMPM improvement year-over-year between vintages). Manageable lowlights include seasonal Q4 headwinds, a large share of early-stage members that will pressure near-term margins until cohorts mature, ongoing CMS appeal litigation risk, and elevated outpatient trends that require monitoring. Overall, the positive operational and financial momentum, upgraded guidance, and stronger star positioning outweigh the remaining risks and seasonal uncertainties.View all CLOV earnings summariesCLOV Stock 12 Month Forecast
Average Price Target
$5.25
▲(27.12% Upside)
Technical Analysis
Ownership Overview
6.86% Insiders
7.81% Mutual Funds
1.21% Other Institutional Investors
72.43% Public Companies and
Individual Investors